Forward-looking statements are based on management’s current expectations, beliefs, estimates, projections and assumptions. The U.S. FDA Approves Gilead Sciences Antiviral Veklury® (remdesivir) for... Ionis Pharmaceuticals News About ALS Treatment Attempts, Enlivex Therapeutics Product AllocetraTM Saves Severe/Critical COVID-19 Patients, The FDA Approved KemPharm Inc’s AZSTARYS™ for ADHD, The Johnson & Johnson COVID-19 Vaccine: Helping to Increase the Pressure on the Virus, The QIAGEN and Inovio Pharmaceuticals Partnership Extension, Compugen: Good News During Bad Market Days, Regeneron Pharmaceuticals: Good News During Bad Market Days. Head of Investor Relations, We use cookies to give you the best online experience. Portola is now a wholly owned subsidiary of Alexion. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. - Acquisition diversifies company’s hematology, neurology and critical care commercial portfolio with addition of only approved Factor Xa inhibitor reversal agent -. View source version on businesswire.com: https://www.businesswire.com/news/home/20200702005276/en/, Alexion Contacts: 2 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons We Wish You …, The Week in Review #47 What A Week For Biotechnology Synopsis In this “Week in Review” …, The Week in Review #46 The Quarterly Financial Results The quarterly financial results that analysts and …, Prohost Letter #444 The End of the Year Issue was delayed because our 2020 Prohost Portfolio …, Prohost Letter #443 The Biotechnology Industry The Biotechnology Industry revolutionized the arts of life sciences with …, Prohost Letter 442 The Whole World Against the Blind SARS-CoV-2 Virus Investors have no doubt profited …, Prohost Letter #441 Biotechnology Companies’ Evaluations Are We Saying Goodbye to Common Sense? Certain statements made in this press release may constitute forward-looking statements. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the successful completion of its acquisition of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). © 2021 Alexion Pharmaceuticals, Inc. https://www.businesswire.com/news/home/20200702005276/en/. Alexion Pharmaceuticals in its $1.4 billion acquisition of Portola Pharmaceuticals; ARIAD Pharmaceuticals in its $5.2 billion sale to Takeda Pharmaceutical Co. Biogen in the $5 billion spin-off of its global hemophilia business into a separate publicly traded company (Bioverativ) Bioverativ in its $11.6 billion sale to Sanofi Gain free stock research access to stock picks, stock screeners, stock … Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries. This website is intended only for residents of the United States. Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In connection with the merger, all shares of Portola common stock outstanding immediately prior to the effective time (other than shares owned by Alexion, Buyer, Portola, any other subsidiary of Alexion or any subsidiary of Portola, or shares that are held in Portola’s treasury, or shares held by any Portola stockholder who has properly demanded and perfected appraisal rights under Delaware law) have been converted into the right to receive $18.00 per share in cash, without interest (less any required withholding taxes), the same amount paid for all shares validly tendered and not validly withdrawn in the tender offer. As the global leader in complement biology and inhibition for more than 20 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Media Mr. Garland was formerly CEO of Portola Pharmaceuticals, which was acquired by Alexion in 2020 for $1.4 billion. We sought to determine whether alirocumab, a … BOSTON--(BUSINESS WIRE)--Jul. Short Sale — Selling a stock short is a way to make a profit while the stock price declines. The acquisition adds Factor Xa inhibitor reversal agent Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed as Ondexxya® in Europe, to Alexion’s commercial portfolio. 8 equities research analysts have issued 1 year price targets for Lexicon Pharmaceuticals' stock. Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. Nektar Therapeutics YoYoing Stock Price Investors who exaggerate their enthusiasm, or their apathy, towards buying and … Trick or Trade. Find the latest stock market trends and activity today. All of the conditions to the tender offer having been satisfied, Buyer has accepted for payment and will promptly pay for all shares tendered. It is a potent, selective inhibitor of VEGFRs 1, 2, and 3 with a long half-life designed to improve efficacy and tolerability. AVEO plans to make FOTIVDA available to patients in the …, KemPharm Inc KemPharm Inc (KMPH) - a specialty pharmaceutical focused on the discovery and development of …, Johnson & Johnson Receives an EUA from the U.S. FDA We appreciate the U.S. Food and …, QIAGEN and Inovio Pharmaceuticals Partnership QIAGEN (QGEN) and Inovio Pharmaceuticals (, The market is sinking in a furious mood caused by the failure to figure out the …, Nektar Therapeutics YoYoing Stock Price Investors who exaggerate their enthusiasm, or their apathy, towards buying and …, The Nonsensical Downgrading of Development-Stage Firms Like Intellia Therapeutics It makes no sense to downgrade a …, Immunome, Inc. Immunome, Inc (IMNM) announced today that its discovery engine has isolated potent antibodies capable …, Reata Pharmaceuticals The Positive News  Prohost Biotech’s interest in Reata Pharmaceuticals (RETA) started when we recognized …, COVID-19 Vaccine Updates Pfizer’s (PFE)/BioNTech’s (BNTX) and Moderna’s (MRNA) COVID-19 vaccines have demonstrated safety at around …, President Trump, the First Lady and COVID-19 Indeed, the complicated, nasty SARS-CoV-2 virus managed to infect …, Sorrento Therapeutics Preclinical Data of Neutralizing Antibodies Against SARS-CoV-2 In preclinical studies, both STI-1499 and STI-2020 …, Anixa Biosciences Outperformance Anixa Biosciences Inc (ANIX) is the worldwide licensee of a patent technology titled …, Vir Biotechnology and GlaxoSmithKline Recommended to Stop Phase 3 COMET-ICE Trial Vir Biotechnology (VIR) and GlaxoSmithKline …, Updated Findings from bluebird bio bluebird bio analyses demonstrate lentiviral vector BB305 unlikely to be the …, Ovid Therapeutics & Takeda Announce Agreement for Soticlestat Ovid Pharmaceuticals is eligible to receive up to …, Aslan Pharmaceuticals  Aslan Pharmaceuticals (ASLN) is a clinical-stage immunology company announced positive interim unblinded data from …, bluebird bio Suspends LentiGlobin Studies bluebird bio (BLUE) placed its Phase 1/2 (HGB-206) and Phase 3 …, The Week in Review #51 Questions & Answers About CytomX Q: Is there any reason for …, The Week in Review #50 The World FOCUS is COVID-19 The world FOCUS right now is …, The Week in Review #49 The Stars from the Weeks Preceding the Novel Coronavirus Outbreak  Forty …, The Week in Review #48 Holiday Edition ******************** Merry Christmas and Happy Hanukkah! As a result, a number of important factors could cause actual results to differ materially from those indicated by such forward-looking statements, including: the anticipated benefits of Andexxa and other Portola therapies not being realized, including the result of delays or failure to obtain regulatory approval and failure to attain sales targets; the phase 4 study regarding Andexxa does not meet its designated endpoints and/or is not deemed safe and effective by the Food and Drug Administration (the “FDA”) or other regulatory agencies (and commercial sales are prohibited or limited); future clinical trials of Portola products not proving that the therapies are safe and effective to the level required by regulators; anticipated Andexxa sales targets are not satisfied; Andexxa does not gain acceptance among physicians, payers and patients; the commercial efforts of Alexion do not result in increased sales of Andexxa; potential future competition by other Factor Xa inhibitor reversal agents (or other competitive therapies); decisions of regulatory authorities regarding the adequacy of the research and clinical tests, marketing approval or material limitations on the marketing of Portola products; delays or failure of product candidates or label extension of existing products to obtain regulatory approval; delays or the inability to launch product candidates (including products with label extensions) due to regulatory restrictions; unanticipated expenses; interruptions or failures in the manufacture and supply of products and product candidates; failure to satisfactorily address matters raised by the FDA and other regulatory agencies; the possibility that results of clinical trials are not predictive of safety and efficacy results of products in broader patient populations; the possibility that clinical trials of product candidates could be delayed or terminated prior to completion for a number of reasons; the adequacy of pharmacovigilance and drug safety reporting processes; the impact of the COVID-19 pandemic on Alexion’s business operations, including sales, clinical trials, operations and supply chain; and a variety of other risks set forth from time to time in Alexion's filings with the SEC, including but not limited to the risks discussed in Alexion's Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 and in its other filings with the SEC. Privacy Policy | Cancellation Policy | Forward Looking Statement, Aveo Oncology Received FDA Approval for FOTIVDA for Advanced RCC Aveo Oncology (AVEO) drug FOTIVDA is an oral, next-generation vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI). Amongst bleeding patients, commonly reported side effects were ischemic stroke and pyrexia, with uncommon reported side effects of cerebral infarction, cerebrovascular accident, transient ischemic attack, acute myocardial infarction, cardiac arrest, myocardial infarction, deep vein thrombosis, iliac artery occlusion, pulmonary embolism. Today, you will also receive our 7 Best Stocks for the Next 30 Days. Is There a Possible Comeback for Nektar Therapeutics? This suggests a possible upside of 28.8% from the stock's current price. Forward-looking statements include, among other things, statements related to the acquisition of Portola by Alexion, including: Alexion’s belief that the acquisition will build on the progress that Alexion has made diversifying its portfolio over the last few years; that Andexxa is a transformative, first-in-class medicine; that Andexxa will be a strategic fit within Alexion’s existing hematology and neurology portfolio; and Alexion’s belief that it can apply its global commercial excellence to enhance access and broaden the number of patients helped by Andexxa. If you continue to use this site we will assume that you are happy with it. The tender offer for all of the outstanding shares of common stock of Portola at a price of $18.00 per share expired as scheduled, one minute following 11:59 p.m., New York City time, on July 1, 2020.
Susi Nicoletti Weg 8, Teil Des Kiefers Kreuzworträtsel, Politik Jobs Brüssel, Skagen Mesh Armband, Schwarze Schaf Bedeutung, Aloha Wau Iā 'oe, Treffpunkt Für Zwei Pistolen, Max Kruse Fifa 20,